Lymphedema affects 10M+ Americans. There is no FDA-approved disease-modifying treatment. SteerBio’s living platform delivers a regenerative growth factor to rebuild the lymphatic system. Built on foundational Rice University bioengineering research, it addresses the root cause of lymphedema rather than its symptoms.

The lead indication is breast cancer-related lymphedema, with multiple additional indications addressable from the same platform.

Progress

• FDA INTERACT meeting completed

• IND-enabling preclinical studies underway

• Series A financing underway

• Backed by the ARPA-H GLIDE program